📊 REGN Key Takeaways
Is Regeneron Pharmaceuticals, Inc.. (REGN) a Good Investment?
Regeneron demonstrates strong operational profitability with 20.2% net margins and robust free cash flow generation of $848.3M, supported by an exceptionally healthy balance sheet with minimal leverage. However, the company faces significant headwinds with anemic 1.0% revenue growth and alarmingly low returns on equity (2.3%) and assets (1.8%), indicating poor capital efficiency and limited growth prospects that constrain upside potential.
Regeneron shows high-quality fundamentals: strong profitability, a 31.4% net margin, robust free cash flow generation, and an exceptionally strong balance sheet with low leverage and ample liquidity. The main limitation is modest recent revenue growth, but the company’s financial resilience and cash-producing capacity support a favorable fundamental outlook if it can sustain pipeline execution and margin discipline.
Why Buy Regeneron Pharmaceuticals, Inc.. Stock? REGN Key Strengths
- Exceptional profitability margins: 20.2% net margin and 17.8% operating margin demonstrate operational excellence
- Fortress balance sheet with minimal leverage (0.06x debt/equity), $3.0B cash, and exceptional interest coverage of 39.9x
- Strong free cash flow generation of $848.3M with 23.5% FCF margin providing capital flexibility
- Outstanding liquidity with 3.57x current ratio and 2.96x quick ratio
- Efficient operational cash conversion with $1.1B operating cash flow from $3.6B revenue
- High profitability with 24.9% operating margin and 31.4% net margin
- Excellent financial health, including 4.13x current ratio and just 0.06x debt-to-equity
- Strong cash generation with $4.08B in free cash flow and 28.4% FCF margin
REGN Stock Risks: Regeneron Pharmaceuticals, Inc.. Investment Risks
- Severely constrained revenue growth at 1.0% YoY suggests mature product portfolio or competitive market pressures
- Critically low ROE of 2.3% and ROA of 1.8% indicate substantial capital allocation inefficiency and value destruction
- Capital-intensive operations requiring $230.6M annual capex with minimal growth outcome
- Revenue growth lagging diluted EPS growth (+8.2%) suggests dependence on share buybacks rather than organic expansion
- Pharmaceutical industry exposure to regulatory, patent cliff, and pricing pressures
- Revenue growth is currently modest at 1.0% YoY, which may limit operating leverage expansion
- Pharmaceutical earnings can be vulnerable to product concentration, patent cliffs, and pipeline execution risk
- Margins could face pressure from R&D intensity, competition, or reimbursement and regulatory changes
Key Metrics to Watch
- Revenue growth acceleration - must exceed 3-5% threshold to validate pharmaceutical company viability
- Return on equity improvement trajectory from current 2.3% baseline
- Operating cash flow sustainability and capital allocation efficiency going forward
- Pipeline contribution and new product revenue recognition rates
- Revenue growth rate and product concentration trends
- Operating margin and free cash flow consistency
Regeneron Pharmaceuticals, Inc.. (REGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 23.5% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.57x current ratio provides a solid financial cushion.
REGN Profit Margin, ROE & Profitability Analysis
REGN vs Healthcare Sector: How Regeneron Pharmaceuticals, Inc.. Compares
How Regeneron Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Regeneron Pharmaceuticals, Inc.. Stock Overvalued? REGN Valuation Analysis 2026
Based on fundamental analysis, Regeneron Pharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Regeneron Pharmaceuticals, Inc.. Balance Sheet: REGN Debt, Cash & Liquidity
REGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Regeneron Pharmaceuticals, Inc..'s revenue has declined by 11% over the 5-year period, indicating business contraction. The most recent EPS of $34.77 reflects profitable operations.
REGN Revenue Growth, EPS Growth & YoY Performance
REGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.0B | $727.2M | $6.75 |
| Q3 2025 | $3.7B | $722.0M | $11.54 |
| Q2 2025 | $3.5B | $722.0M | $12.41 |
| Q1 2025 | $3.0B | $722.0M | $6.27 |
| Q3 2024 | $3.4B | $722.0M | $8.89 |
| Q2 2024 | $3.2B | $722.0M | $8.50 |
| Q1 2024 | $3.1B | $722.0M | $6.27 |
| Q3 2023 | $2.9B | $817.8M | $8.89 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Regeneron Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
REGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Regeneron Pharmaceuticals, Inc.. (CIK: 0000872589)
📋 Recent SEC Filings
❓ Frequently Asked Questions about REGN
What is the AI rating for REGN?
Regeneron Pharmaceuticals, Inc.. (REGN) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are REGN's key strengths?
Claude: Exceptional profitability margins: 20.2% net margin and 17.8% operating margin demonstrate operational excellence. Fortress balance sheet with minimal leverage (0.06x debt/equity), $3.0B cash, and exceptional interest coverage of 39.9x. ChatGPT: High profitability with 24.9% operating margin and 31.4% net margin. Excellent financial health, including 4.13x current ratio and just 0.06x debt-to-equity.
What are the risks of investing in REGN?
Claude: Severely constrained revenue growth at 1.0% YoY suggests mature product portfolio or competitive market pressures. Critically low ROE of 2.3% and ROA of 1.8% indicate substantial capital allocation inefficiency and value destruction. ChatGPT: Revenue growth is currently modest at 1.0% YoY, which may limit operating leverage expansion. Pharmaceutical earnings can be vulnerable to product concentration, patent cliffs, and pipeline execution risk.
What is REGN's revenue and growth?
Regeneron Pharmaceuticals, Inc.. reported revenue of $3.6B.
Does REGN pay dividends?
Regeneron Pharmaceuticals, Inc.. pays dividends, with $97.8M distributed to shareholders in the trailing twelve months.
Where can I find REGN SEC filings?
Official SEC filings for Regeneron Pharmaceuticals, Inc.. (CIK: 0000872589) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is REGN's EPS?
Regeneron Pharmaceuticals, Inc.. has a diluted EPS of $6.75.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is REGN a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Regeneron Pharmaceuticals, Inc.. has a BUY rating with 80% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is REGN stock overvalued or undervalued?
Valuation metrics for REGN: ROE of 2.3% (sector avg: 15%), net margin of 20.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy REGN stock in 2026?
Our dual AI analysis gives Regeneron Pharmaceuticals, Inc.. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is REGN's free cash flow?
Regeneron Pharmaceuticals, Inc..'s operating cash flow is $1.1B, with capital expenditures of $230.6M. FCF margin is 23.5%.
How does REGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 20.2% (avg: 12%), ROE 2.3% (avg: 15%), current ratio 3.57 (avg: 2).